Oncology Corporate Profile
3.4600 | |
0.1300 |
BioLineRx is a publicly-traded, clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates. The Company in-licenses novel compounds primarily from academic institutions and biotech companies based in Israel, develops them through pre-clinical and/or clinical stages, and then partners with pharmaceutical companies for advanced clinical development and/or commercialization.
Website: http://www.BiolineRx.com
Brand / Product | Class | Area of Study | Phase | Partnership |
---|---|---|---|---|
BL-8040 | CXCR4 peptide inhibitor | Various cancer types | II | |
BL-8040 (+ atezolizumab) | CXCR4 peptide inhibitor | Acute Myelogenous Leukemia (AML) | I | Genentech/Roche |
AGI-134 | immunotherapy | Various cancer types | Preclinical |
View additional information on product candidates here »